Covid-19 roundup: Sh­iono­gi’s an­tivi­ral pill hits the mark; Ocu­gen strikes deal for in­tranasal vac­cine

Japan­ese phar­ma Sh­iono­gi’s Covid-19 an­tivi­ral against Omi­cron passed its Phase III tri­al in Asia, meet­ing its pri­ma­ry end­point.

The drug, a pro­tease in­hibitor known as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.